Gentian Diagnostics ASA
OSE:GENT
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
NO |
G
|
Gentian Diagnostics ASA
OSE:GENT
|
632.3m NOK | 63.1 | |
CH |
Alcon AG
SIX:ALC
|
39.8B CHF | 83.4 | ||
JP |
Hoya Corp
TSE:7741
|
6.7T JPY | 41.9 | ||
DK |
Coloplast A/S
CSE:COLO B
|
184.5B DKK | 70.3 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
19.2B USD | 31.6 | ||
US |
Cooper Companies Inc
NYSE:COO
|
18.7B USD | 80 | ||
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
59.5B CNY | 52.6 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.1B GBP | 38.2 | ||
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.8B USD | 26.4 | ||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -91.5 | |
CH |
Ypsomed Holding AG
SIX:YPSN
|
5.2B CHF | -613.1 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.